Trial Profile
A Dose-Finding Study of OPC-6535 in Patients With Active Crohn's Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Tetomilast (Primary) ; Mesalazine
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 12 May 2014 New trial record
- 12 Oct 2007
- 20 Sep 2006